Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000993 · ClinicalTrials.gov registry record · NA
A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
NCT00000993 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID).
The verdict
NCT00000993, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To prevent individuals who have had a massive accidental exposure to HIV from becoming infected with HIV and possibly developing AIDS, by treating them with zidovudine (AZT). Although the number of persons who have been (or will be) exposed to a high concentration of HIV is quite small, these persons have a high risk of becoming infected and treatments are needed to prevent infection after such an exposure. In animal studies, AZT has prevented the development of infections after exposure of the animals to a retrovirus (the HIV is a retrovirus). In patients with AIDS, AZT has been effective in delaying the progression of the disease. For these reasons a trial of AZT is indicated.
Interventions
- DRUG Zidovudine
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000993
The ClinicalTrials.gov registry entry for NCT00000993 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zidovudine is the first listed.
NCT00000993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000993 about?
NCT00000993 is a clinical study titled "A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus". To prevent individuals who have had a massive accidental exposure to HIV from becoming infected with HIV and possibly developing AIDS, by treating them with zidovudine (AZT). Although the number of persons who have been (or will be) exposed to a high concentration of HIV is quite small, these person...
What is the current status of trial NCT00000993?
This trial is currently completed. It is a NA study. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00000993?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00000993?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.